Aging shifts the striatal dopamine receptor balance toward D1 dominance, which actively suppresses autophagy through a GSK-3β‑dependent mechanism that converges with mTORC1‑TFEB dysregulation. We hypothesize that heightened D1 receptor signaling increases GSK-3β activity, leading to phosphorylation of TFEB at serine residues distinct from those targeted by mTORC1. This dual phosphorylation promotes tighter binding of TFEB to cytoplasmic 14-3-3 proteins, preventing its nuclear translocation and transcriptional activation of autophagy and lysosomal genes. Consequently, autophagic flux declines, damaged mitochondria and α‑synuclein aggregates accumulate, and habit‑formation circuits deteriorate.

Mechanistic rationale: D1 receptors couple to Gαs/adenylyl cyclase/PKA signaling. In aged neurons, chronic PKA activation can inhibit Akt, relieving inhibitory phosphorylation of GSK-3β (Ser9) and thereby increasing its kinase activity toward TFEB. This pathway operates parallel to mTORC1, which also phosphorylates TFEB but at different sites (Ser142, Ser138). The combined actions create a synergistic brake on TFEB nuclear entry. Supporting this, GSK-3β inhibition restores TFEB nuclear localization in senescent cells, and D2 receptor activation opposes GSK-3β activity via PI3K/Akt signaling.

Testable predictions:

1. In aged rat striatum, D1 receptor overexpression will increase GSK-3β activity (measured by decreased p‑GSK-3βSer9) and reduce nuclear TFEB, whereas D2 knock‑down will produce the same effect.
2. Pharmacological blockade of D1 receptors (SCH23390) or activation of D2 receptors (quinpirole) in aged animals will decrease GSK-3β activity, increase nuclear TFEB, and rescue autophagic flux (LC3‑II/I ratio, p62 degradation) without altering mTORC1 phosphorylation status.
3. These manipulations will lower insoluble α‑synuclein levels and improve performance on habit‑learning tasks (e.g., progressive‑ratio lever pressing) in aged rats.

Experimental design: Use 24‑month‑old male Fischer‑344 rats. Groups receive intracerebroventricular infusion of either vehicle, D1 antagonist, D2 agonist, or combined treatment for two weeks. Assess GSK-3β activity (Western blot for p‑GSK-3βSer9), TFEB subcellular localization (immunofluorescence and fractionation), autophagic flux (LC3 turnover with bafilomycin A1), α‑synuclein solubility (RIPA vs. SDS extracts), and behavior on a habit‑acquisition assay. Include young adult controls to confirm age‑specific effects.

Falsifiability: If D1/D2 modulation fails to alter GSK-3β activity, TFEB localization, or autophagic flux despite expected receptor engagement, or if behavioral improvements occur without changes in autophagy markers, the hypothesis would be refuted. This framework directly links dopaminergic signaling to the active suppression of autophagy in aging basal ganglia, offering a mechanistic bridge between receptor imbalance, organelle quality control, and cognitive decline.